Cargando…
Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes
Autores principales: | Davis, PM, Nadler, SG, Rouleau, KA, Suchard, SJ |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834020/ http://dx.doi.org/10.1186/ar1542 |
Ejemplares similares
-
Prophylactic administration of abatacept (CTLA4-Ig; BMS-188667) prevents disease induction and bone destruction in a rat model of collagen-induced arthritis
por: Kliwinski, C, et al.
Publicado: (2005) -
Effects of CTLA4-Ig on human monocytes
por: Tono, Toshihiro, et al.
Publicado: (2017) -
Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency
por: Yang, Lu, et al.
Publicado: (2020) -
Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004) -
CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
por: Pieper, Jennifer, et al.
Publicado: (2013)